{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:00:35Z","timestamp":1775545235576,"version":"3.50.1"},"reference-count":45,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK060"],"award-info":[{"award-number":["SZXK060"]}]},{"name":"Science and Technology Research Project of Hubei Province","award":["2013BCB002"],"award-info":[{"award-number":["2013BCB002"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alport syndrome (AS) is one of the most common fatal hereditary renal diseases in human, with a high risk of progressing to end-stage renal disease without effective treatments. Mesenchymal stem cells (MSCs) have recently emerged as a promising therapeutic strategy for chronic kidney disease. However, the safety and therapeutic potential of MSC transfusion for patients with AS are still need to be confirmed. Therefore, we have designed a clinical trial to evaluate the hypothesis that intravenous infusion of human umbilical cord-derived MSC (hUC-MSC) is safe, feasible, and well-tolerated in children with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We report the protocol of the first prospective, open-label, single-arm clinical trial to evaluate the safety and preliminary efficacy of hUC-MSC transfusion in children with early-stage AS. Paediatric patients diagnosed with AS who have persistent albuminuria will be candidates for screening. Twelve eligible patients are planned to recruit and will receive hUC-MSC infusions under close safety monitoring, and complete the efficacy assessments at scheduled follow-up visits. The primary endpoints include the occurrence of adverse events to assess safety and the albuminuria level for efficacy evaluation. Secondary endpoint assessments are based on haematuria and glomerular filtration measurements. Each patient\u2019s efficacy endpoints will be evaluated against their baseline levels. Additionally, the underlying mechanism of hUC-MSC therapy will be explored through transcriptomic and proteomic analysis of blood and urine samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The protocol (V.1.0, date 17 January 2015) was approved by the institutional review board of the Affiliated Taihe Hospital of Hubei University of Medicine (ethical approval 03 March 2015). Written informed consent will be obtained from the patient and\/or guardians before study specific process. In addition to publication in a peer-reviewed scientific journal, a lay summary of study will be available for participants and the public on the Chinese Organization for Rare Disorders website (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cord.org.cn\/\">http:\/\/www.cord.org.cn\/<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN62094626\">ISRCTN62094626<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-075138","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:50:10Z","timestamp":1710499810000},"page":"e075138","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn62094626","registry":"10.18810\/isrctn"}],"author":[{"given":"Li","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[{"name":"Hainan Women and Children's Medical Center, Haikou, Hainan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Taihe Hospital, Shiyan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaowei","family":"Gu","sequence":"additional","affiliation":[{"name":"Taihe Hospital, Shiyan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-4306","authenticated-orcid":false,"given":"Che","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, South China Hospital, Medical School, Shenzhen University, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2025120601123299000_14.3.e075138.1","doi-asserted-by":"crossref","unstructured":"Kelly YP , Wallis L , Patil A , et al . Alport syndrome: no evidence of improved prognosis in modern era. J Clin Nephrol Ren Care 2018;4. doi:10.23937\/2572-3286.1510036 Available: https:\/\/www.clinmedjournals.org\/archives_search.php?jid=jcnrc&volume=4&issue=1","DOI":"10.23937\/2572-3286.1510036"},{"key":"2025120601123299000_14.3.e075138.2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V114649"},{"key":"2025120601123299000_14.3.e075138.3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012020148"},{"key":"2025120601123299000_14.3.e075138.4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00467-017-3784-3","article-title":"Renal, Auricular, and ocular outcomes of Alport syndrome and their current management","volume":"33","author":"Zhang","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2025120601123299000_14.3.e075138.5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010090965"},{"key":"2025120601123299000_14.3.e075138.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.018"},{"key":"2025120601123299000_14.3.e075138.7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.407"},{"key":"2025120601123299000_14.3.e075138.8","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.951328"},{"key":"2025120601123299000_14.3.e075138.9","doi-asserted-by":"crossref","unstructured":"Chavez E , Rodriguez J , Drexler Y , et al . Novel therapies for Alport syndrome. Front Med (Lausanne) 2022;9. doi:10.3389\/fmed.2022.848389","DOI":"10.3389\/fmed.2022.848389"},{"key":"2025120601123299000_14.3.e075138.10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018010091"},{"key":"2025120601123299000_14.3.e075138.11","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2019.12.015"},{"key":"2025120601123299000_14.3.e075138.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.08.024"},{"key":"2025120601123299000_14.3.e075138.13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021101286"},{"key":"2025120601123299000_14.3.e075138.14","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.060158"},{"key":"2025120601123299000_14.3.e075138.15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00779.x"},{"key":"2025120601123299000_14.3.e075138.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.06.031"},{"key":"2025120601123299000_14.3.e075138.17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021040577"},{"key":"2025120601123299000_14.3.e075138.18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000513777","article-title":"Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of Bardoxolone methyl in patients with Alport syndrome","volume":"52","author":"Chertow","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025120601123299000_14.3.e075138.19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","article-title":"Allogeneic Mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy","volume":"33","author":"Gu","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025120601123299000_14.3.e075138.20","doi-asserted-by":"crossref","unstructured":"Yuan X , Qin X , Wang D , et al . Mesenchymal stem cell therapy induces Flt3L and Cd1C+ Dendritic cells in systemic lupus erythematosus patients. Nat Commun 2019;10. doi:10.1038\/s41467-019-10491-8","DOI":"10.1038\/s41467-019-10491-8"},{"key":"2025120601123299000_14.3.e075138.21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lfs.2018.11.001","article-title":"Paracrine effect of Mesenchymal stem cell as a novel therapeutic strategy for diabetic nephropathy","volume":"215","author":"Li","year":"2018","journal-title":"Life Sci"},{"key":"2025120601123299000_14.3.e075138.22","doi-asserted-by":"crossref","unstructured":"Li H , Rong P , Ma X , et al . Mouse umbilical cord Mesenchymal stem cell Paracrine Alleviates renal fibrosis in diabetic nephropathy by reducing Myofibroblast Transdifferentiation and cell proliferation and Upregulating Mmps in mesangial cells. J Diabetes Res 2020. doi:10.1155\/2020\/3847171","DOI":"10.1155\/2020\/3847171"},{"key":"2025120601123299000_14.3.e075138.23","first-page":"2629","article-title":"Early intervention with Mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory Microenvironment","volume":"41","author":"Li","year":"2018","journal-title":"Int J Mol Med"},{"key":"2025120601123299000_14.3.e075138.24","doi-asserted-by":"crossref","unstructured":"Shi Y , Xie J , Yang M , et al . Transplantation of umbilical cord Mesenchymal stem cells into mice with focal segmental Glomerulosclerosis delayed disease manifestation. Ann Transl Med 2019;7. doi:10.21037\/atm.2019.07.71","DOI":"10.21037\/atm.2019.07.71"},{"key":"2025120601123299000_14.3.e075138.25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/scd.2015.0305","article-title":"Human chorionic stem cells Podocyte differentiation and potential for the treatment of Alport syndrome","volume":"25","author":"Moschidou","year":"2016","journal-title":"Stem Cells Dev"},{"key":"2025120601123299000_14.3.e075138.26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001521"},{"key":"2025120601123299000_14.3.e075138.27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/0963689717729379","article-title":"A randomized, placebo-controlled trial of human umbilical cord blood Mesenchymal stem cell infusion for children with cerebral palsy","volume":"27","author":"Huang","year":"2018","journal-title":"Cell Transplant"},{"key":"2025120601123299000_14.3.e075138.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-019-1545-x","article-title":"Therapeutic evidence of umbilical cord-derived Mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial","volume":"11","author":"Gu","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"2025120601123299000_14.3.e075138.29","unstructured":"National Center for Drug Evaluation . Statistical principles for clinical trials on drugs for rare diseases. 2022. Available: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/058e0d665b785e79b7f4f24dc1dc970c"},{"key":"2025120601123299000_14.3.e075138.30","doi-asserted-by":"crossref","unstructured":"Chan A-W , Tetzlaff JM , G\u00f8tzsche PC , et al . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013. doi:10.1136\/bmj.e7586","DOI":"10.1136\/bmj.e7586"},{"key":"2025120601123299000_14.3.e075138.31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.xkme.2020.05.014","article-title":"Alport syndrome classification and management","volume":"2","author":"Warady","year":"2020","journal-title":"Kidney Med"},{"key":"2025120601123299000_14.3.e075138.32","doi-asserted-by":"crossref","unstructured":"Szczepiorkowski ZM , Nunes E . AABB cell therapy standards. Cell Therapy 2009:87\u201395. doi:10.1007\/b102110","DOI":"10.1007\/b102110_8"},{"key":"2025120601123299000_14.3.e075138.33","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905."},{"key":"2025120601123299000_14.3.e075138.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.08.002"},{"key":"2025120601123299000_14.3.e075138.35","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0201"},{"key":"2025120601123299000_14.3.e075138.36","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-269043"},{"key":"2025120601123299000_14.3.e075138.37","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic Mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang","year":"2013","journal-title":"Cell Transplant"},{"key":"2025120601123299000_14.3.e075138.38","unstructured":"National Health Commission of China . Standardfor height Levelclassificationamong children and adolescents aged 7-18 years. 2018. Available: chrome-extension:\/\/ibllepbpahcoppkjjllbabhnigcbffpi\/http:\/\/www.nhc.gov.cn\/ewebeditor\/uploadfile\/2018\/07\/20180705095132166.pdf"},{"key":"2025120601123299000_14.3.e075138.39","unstructured":"Ministry of Education . National Standards for Students Physical Health, Available: http:\/\/www.moe.gov.cn\/s78\/A17\/twys_left\/moe_938\/moe_792\/s3273\/201407\/t20140708_171692.html"},{"key":"2025120601123299000_14.3.e075138.40","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S225613"},{"key":"2025120601123299000_14.3.e075138.41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4239\/wjd.v13.i10.877","article-title":"Effectiveness and safety of human umbilical cord-Mesenchymal stem cells for treating type 2 diabetes mellitus","volume":"13","author":"Lian","year":"2022","journal-title":"World J Diabetes"},{"key":"2025120601123299000_14.3.e075138.42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5009\/gnl17035","article-title":"Umbilical cord Mesenchymal stem cell treatment for Crohn\u2019s disease: A randomized controlled clinical trial","volume":"12","author":"Zhang","year":"2018","journal-title":"Gut Liver"},{"key":"2025120601123299000_14.3.e075138.43","doi-asserted-by":"crossref","unstructured":"Wang Y , Yi H , Song Y . The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther 2021;12. doi:10.1186\/s13287-021-02609-x","DOI":"10.1186\/s13287-021-02609-x"},{"key":"2025120601123299000_14.3.e075138.44","doi-asserted-by":"crossref","unstructured":"Lin W , Li H-Y , Yang Q , et al . Administration of Mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis. Stem Cell Res Ther 2021. doi:10.1186\/s13287-020-02108-5","DOI":"10.21203\/rs.3.rs-70844\/v3"},{"key":"2025120601123299000_14.3.e075138.45","doi-asserted-by":"crossref","unstructured":"Li A , Guo F , Pan Q , et al . Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus. Front Immunol 2021. doi:10.3389\/fimmu.2021.728190","DOI":"10.3389\/fimmu.2021.728190"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-075138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:12:45Z","timestamp":1765012365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-075138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bmjopen-2023-075138"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-075138","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}